天圣制药(002872) - 2025 Q2 - 季度业绩预告

Core Summary of Performance Forecast H1 2025 net loss attributable to shareholders is projected to narrow from RMB 43.11 million to RMB 30-42 million 2025 Half-Year Performance Forecast | Item | Current Period (2025 H1 Estimated) | Prior-Year Period (2024 H1) | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Loss: RMB 30 million – RMB 42 million | Loss: RMB 43.1081 million | | Net Profit After Deducting Non-Recurring Gains and Losses | Loss: RMB 35 million – RMB 48 million | Loss: RMB 47.3182 million | | Basic Earnings Per Share | Loss: RMB 0.0943/share – RMB 0.1321/share | Loss: RMB 0.1356/share | Analysis of Performance Changes Continued losses are primarily due to high fixed costs, notably fixed asset depreciation, impacting profitability - The company attributes the performance loss to higher fixed expenses, especially depreciation costs for fixed assets[5] Other Significant Matters Unaudited forecast data, communicated with auditors without major discrepancies, is preliminary; final figures will be in the 2025 half-year report - The performance forecast data for this period has not been pre-audited by a certified public accountant, but the company has pre-communicated with the accounting firm, and there are no significant disagreements between the parties[4] - The company advises that this performance forecast is a preliminary estimate by the finance department, and the final data will be subject to the 2025 half-year report; investors are urged to make cautious decisions[6]